Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD9750 |
| Synonyms | |
| Therapy Description |
AZD9750 is a proteolysis targeting chimera (PROTAC) targeting the androgen receptor (AR), which potentially induces AR degradation and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4758). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD9750 | AZD-9750|AZD 9750 | Hormone - Anti-androgens 58 | AZD9750 is a proteolysis targeting chimera (PROTAC) targeting the androgen receptor (AR), which potentially induces AR degradation and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4758). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07336446 | Phase Ib/II | AZD9750 + Saruparib AZD9750 | A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs (ANDROMEDA) | Not yet recruiting | USA | CAN | AUS | 1 |